William Blair Issues Positive Estimate for ZVRA Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Equities researchers at William Blair increased their Q2 2025 earnings estimates for shares of Zevra Therapeutics in a report issued on Monday, July 14th. William Blair analyst S. Corwin now anticipates that the company will post earnings of $2.26 per share for the quarter, up from their previous forecast of $0.09. The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.95) per share. William Blair also issued estimates for Zevra Therapeutics' FY2025 earnings at $2.08 EPS and FY2026 earnings at $0.13 EPS.

Several other analysts also recently commented on ZVRA. Citigroup reaffirmed an "outperform" rating on shares of Zevra Therapeutics in a report on Wednesday, May 14th. Wall Street Zen upgraded shares of Zevra Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Saturday, July 12th. Cantor Fitzgerald increased their price objective on shares of Zevra Therapeutics from $25.00 to $29.00 and gave the stock an "overweight" rating in a research note on Thursday, July 10th. Finally, HC Wainwright assumed coverage on shares of Zevra Therapeutics in a research note on Wednesday, July 2nd. They issued a "buy" rating and a $26.00 price objective on the stock. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Zevra Therapeutics presently has an average rating of "Buy" and an average price target of $23.71.

Zevra Therapeutics Stock Down 4.7%

Shares of NASDAQ ZVRA traded down $0.59 during trading hours on Wednesday, hitting $12.07. 1,200,309 shares of the stock were exchanged, compared to its average volume of 737,476. The company has a market cap of $659.99 million, a PE ratio of -6.35 and a beta of 1.97. Zevra Therapeutics has a 12 month low of $5.45 and a 12 month high of $13.16. The company has a quick ratio of 2.93, a current ratio of 3.02 and a debt-to-equity ratio of 1.46. The firm has a fifty day moving average price of $9.54 and a 200-day moving average price of $8.35.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.15. The business had revenue of $20.40 million during the quarter, compared to analyst estimates of $16.96 million. Zevra Therapeutics had a negative net margin of 226.78% and a negative return on equity of 201.05%. During the same quarter in the previous year, the business posted ($0.40) EPS.

Institutional Trading of Zevra Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ZVRA. BNP Paribas Financial Markets purchased a new position in Zevra Therapeutics during the 4th quarter worth $53,000. GAMMA Investing LLC raised its position in Zevra Therapeutics by 20,564.1% during the 1st quarter. GAMMA Investing LLC now owns 8,059 shares of the company's stock worth $60,000 after buying an additional 8,020 shares during the last quarter. Strs Ohio purchased a new position in Zevra Therapeutics during the 1st quarter worth $125,000. Squarepoint Ops LLC raised its position in Zevra Therapeutics by 36.1% during the 4th quarter. Squarepoint Ops LLC now owns 16,534 shares of the company's stock worth $138,000 after buying an additional 4,384 shares during the last quarter. Finally, ProShare Advisors LLC purchased a new position in Zevra Therapeutics during the 4th quarter worth $145,000. Hedge funds and other institutional investors own 35.03% of the company's stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.